In contrast, PI3Kα inhibitors such as alpelisib (45) and inavolisib (72), as well as the AKT inhibitor capivasertib (50), remain in clinical use for specific cancer types, with ongoing efforts to mitigate side effects, such as hyperglycemia, through the development of mutant-selective inhibitors like STX-478 (35) and RLY-2608 (34). This evidence concerns the gene AKT1 and Hyperglycemia.